Saturday 17 October 2026
Export TMCI’s income statement to Excel — free account
Treace Medical Concepts, Inc.
TMCI Healthcare Medical Devices
Treace Medical Concepts, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $212.7 million, up 1.59% from fiscal 2024. In the quarter to June 2026, revenue fell 4.24%, EPS grew 14.3%, free cash flow grew 11.7% and total debt rose 4.84%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
3.87
0.25
−6.07%
Follow TMCI
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Piotroski F-Score |
2 | 4 | 3 | 1 | — | — | — | — |
Altman Z-Score |
(0.11) | 2.25 | 4.14 | 7.94 | 12.23 | — | — | — |
P/S ratio |
0.73 | 2.21 | 4.08 | 8.73 | 9.56 | 14.91 | 14.91 | — |
Altman Z″-Score (non-manufacturers) |
(1.79) | 0.38 | 2.15 | 1.69 | 5.87 | 3.10 | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Beneish M-Score |
(3.51) | (2.81) | (2.05) | (2.44) | (1.89) | — | — | — |
P/Operating CF |
(19.31) | (109.84) | 1,436.66 | (230.99) | (240.53) | (2,166.88) | (2,166.88) | — |
P/B ratio |
1.77 | 4.09 | 5.54 | 20.45 | 9.70 | 0.00 | 0.00 | — |
Price to Tangible BV |
2.30 | 5.02 | 6.58 | 20.45 | 9.70 | 0.00 | 0.00 | — |
EV/Sales |
0.77 | 2.11 | 3.72 | 8.54 | 8.77 | 15.14 | 15.14 | — |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 524.01 | 524.01 | — |
EV/Operating CF |
(10.27) | (11.88) | (20.13) | (39.51) | (48.16) | (242.64) | (242.64) | — |
EV/FCF |
(5.56) | (9.06) | (15.12) | (26.62) | (41.61) | (211.71) | (211.71) | — |
Quick Ratio |
2.95 | 3.34 | 3.58 | 3.65 | 6.83 | 2.81 | 3.08 | — |
Current Ratio |
4.31 | 4.62 | 4.40 | 4.41 | 7.58 | 3.53 | 3.90 | — |
Net Debt/EBITDA |
(0.17) | 0.46 | 1.49 | 0.88 | 4.88 | 5.75 | (2.73) | — |
Debt/Assets |
29.17% | 24.55% | 21.04% | 33.15% | 20.98% | 74.68% | 0.00% | 0.00% |
Debt/Equity |
0.64 | 0.47 | 0.38 | 0.87 | 0.32 | 40.23 | 0.00 | — |
Asset Turnover |
1.04 | 0.89 | 0.91 | 0.95 | 1.03 | 2.74 | 0.00 | — |
Operating CF/Net income |
0.27 | 0.67 | 0.70 | 0.72 | 0.83 | 1.04 | 1.56 | — |
Capex/Depreciation |
(1.25) | (1.53) | (2.70) | (6.59) | (3.14) | (0.75) | (1.29) | — |
Interest Coverage |
(10.18) | (10.60) | (9.95) | (7.92) | (4.07) | 0.31 | (4.20) | — |
| (58.94%) | (44.45%) | (49.91%) | (55.75%) | (48.30%) | 72.20% | 82.21% | — | |
| (28.95%) | (23.77%) | (24.10%) | (28.56%) | (22.72%) | (20.61%) | 0.00% | — | |
ROIC |
(35.80%) | (38.45%) | (47.44%) | (68.08%) | (61.50%) | 3.84% | (31.19%) | — |
Return on Tangible Assets |
(44.98%) | (36.57%) | (28.20%) | (36.13%) | (16.92%) | (14.26%) | (21.91%) | — |
Average Days of Receivables |
72.34 | 71.14 | 74.25 | 75.13 | 71.78 | 92.17 | 96.41 | — |
Research and Development Expense of Revenue |
9.54% | 9.83% | 8.25% | 9.58% | 10.81% | 10.19% | 12.86% | — |
Selling, General and Administrative Expense of Revenue |
95.74% | 97.14% | 100.43% | 96.99% | 88.79% | 66.58% | 76.75% | — |
Intangible Assets out of Total Assets |
0.10 | 0.10 | 0.09 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
15.90% | 14.62% | 9.27% | 5.72% | 3.61% | 1.60% | 2.07% | — |
Graham Net Nets |
0.19 | 0.12 | 0.11 | 0.03 | 0.10 | 0.00 | 0.00 | — |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.66 | 0.00 | — |
Earnings Yield |
(38.37%) | (12.10%) | (6.45%) | (3.44%) | (2.20%) | (0.49%) | (0.49%) | — |
Free Cash Flow Yield |
(19.02%) | (10.55%) | (6.02%) | (3.68%) | (2.20%) | (0.48%) | (0.48%) | — |
Revenue per Share |
3.36 | 3.37 | 3.08 | 2.57 | 1.95 | 1.55 | 1.07 | — |
Operating CF per Share |
(0.25) | (0.60) | (0.57) | (0.55) | (0.36) | (0.12) | (0.21) | — |
Capex per Share |
(0.21) | (0.19) | (0.19) | (0.27) | (0.06) | (0.03) | (0.03) | — |
Free Cash Flow per Share |
(0.47) | (0.78) | (0.76) | (0.82) | (0.41) | (0.15) | (0.24) | — |
Cash per Share |
0.76 | 1.22 | 2.02 | 1.47 | 2.19 | 0.49 | 0.33 | — |
Shareholders Equity per Share |
1.38 | 1.82 | 2.27 | 1.10 | 1.92 | 0.02 | 0.00 | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
1.38 | 1.82 | 2.27 | 1.10 | 1.92 | 0.02 | 0.00 | — |
Free Cash Flow |
(29.49) | (48.76) | (46.03) | (45.49) | (19.90) | (5.56) | (8.88) | — |
Working Capital |
101.42 | 126.48 | 153.33 | 103.16 | 119.76 | 29.38 | 21.24 | — |
Capital Expenditures |
(13.52) | (11.59) | (11.46) | (14.84) | (2.70) | (1.07) | (1.21) | — |
Net Current Asset Value |
28.81 | 57.20 | 84.39 | 34.91 | 90.22 | (0.05) | 28.57 | — |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1,505.34 | 1,505.34 | — |
Capex to Sales |
0.06 | 0.06 | 0.06 | 0.10 | 0.03 | 0.02 | 0.03 | — |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1,482.26 | 1,482.26 | — |
| Other line items | ||||||||
Depreciation/Fixed assets |
0.36 | 0.29 | 0.19 | 0.15 | 0.30 | 1.73 | 0.82 | — |
Cash ROIC |
(15.42%) | (20.16%) | (14.65%) | (23.39%) | (8.71%) | (11.11%) | (28.33%) | — |
Accounts Receivable Turnover |
5.13 | 5.31 | 5.56 | 5.94 | 5.71 | 4.61 | 3.17 | — |
Accounts Payable Turnover |
4.98 | 3.68 | 3.43 | 4.01 | 5.34 | 7.80 | 4.78 | — |
Inventory Turnover |
1.14 | 1.20 | 1.45 | 1.71 | 1.84 | 1.86 | 1.14 | — |
Average Days of Payables |
57.18 | 93.46 | 122.79 | 123.92 | 87.66 | 66.30 | 44.53 | — |
Days of Inventory on Hand |
306.29 | 348.67 | 303.41 | 276.34 | 228.25 | 228.89 | 266.04 | — |
Average Receivables |
41.48 | 39.43 | 33.63 | 23.88 | 16.53 | 12.45 | 12.45 | — |
Average Payables |
8.62 | 11.18 | 10.25 | 6.36 | 3.16 | 1.60 | 1.60 | — |
Average Inventory |
37.64 | 34.25 | 24.29 | 14.95 | 9.19 | 6.69 | 6.69 | — |
Average Assets |
203.84 | 234.50 | 205.47 | 149.92 | 91.31 | 20.90 | 0.00 | — |
Average Common Equity |
100.11 | 125.42 | 99.23 | 76.80 | 42.96 | (5.97) | (5.97) | — |
Columns are period end dates